single0.15MG
HMG
0.15MG Protocol
HMG 0.15MG/75IU
Injection Freq.
Inject three times per week
Cycle Sched.
Minimum 12 weeks; may extend to 16 weeks based on response
Reconstitution
3.0 mL BAC water
Stimulates spermatogenesis in male secondary infertility/hypogonadotropic states
Improves sperm motility, morphology, and concentration when combined with hCG
Increased pregnancy rates reported in fertility-treatment contexts
Supports normal testicular function and hormone production
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–12 | 75 IU (0.15 mg) | 300 |
| 2 | Weeks 13–16 | 75 IU (0.15 mg) | 300 |
Inject three times per week
Minimum 12 weeks; may extend to 16 weeks based on response
HMG (human menopausal gonadotropin) is described as providing both FSH and LH activity in an approximately 1:1 ratio, derived from purified human menopausal urine. The protocol frames its role in male fertility as filling a key gap when LH-like stimulation alone is insufficient: FSH signaling is described as essential for spermatogenesis and Sertoli-cell support. In men with hypogonadotropic hypogonadism, the page explains that hCG is often used to provide LH-like stimulation; if sperm production remains inadequate, adding HMG supplies the missing FSH activity needed to support testicular function and fertility. The mechanism is therefore endocrine replacement/augmentation—restoring gonadotropin signals to drive sperm production and normalize testicular physiology. The protocol cites clinical studies in which combined HMG + hCG therapy improved sperm concentration, motility, and morphology and increased pregnancy rates in couples undergoing fertility treatment. Overall, it is positioned as a clinically grounded gonadotropin approach with monitoring-based safety considerations.
Injection-site reactions (redness/swelling/mild pain)
Headache, fatigue, or mood changes (uncommon)
Gynecomastia risk (hormonal stimulation)
Overstimulation effects if excessive dosing (rare with monitoring)
Allergic reactions (rare)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)